Brought to you by 
Merck will develop Dov depression candidates
Aug 2004
Executive Summary
Dov Pharmaceutical (in-licenses and develops compounds for treating CNS and CV diseases that involve alterations in neuronal processing) is licensing two clinical-phase triple uptake inhibitors to Merck for development against depression and other psychiatric illnesses. Dov's 8K of 9/22/04 adds that Merck also received rights of first refusal regarding another triple uptake inhibitor, DOV 102,677 (preclinical; for anxiety or depression) under certain circumstances and for additional payment.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R+D and Marketing-Licensing
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck will develop Dov depression candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice